Ann: Binding Term Sheet Signed with Ravi Krishnan, page-11

MYQ is very much undervalued.

Potentially $20M in annual revenue expected to flow beginning from next year (Fitocracy $9M USD + Stepathlon Integration).

This excludes the $1.5M USD license fee from the Stepathlon deal and revenue from the BCT JV. Not to mention any other deals the company is working on.

The great thing about the Stepathlon deal is that businesses are paying for their employees to use their annual program, not the individual. Corporate wellness is such a huge market.

$1 should be reached swiftly once the market catches on.